AN IN-SILICO ANALYSIS TO FIND POTENT INHIBITORS OF ALPHA SYNUCLEIN AGGREGATION FOR THE TREATMENT OF PARKINSON'S DISEASE

Abstract

Parkinson's disease is amongst the most common neurodegenerative diseases (NDD) in elders. It involves gradual degeneration of the dopamine-producing neurons, and is a main neuropathological characteristic of PD. Alpha synuclein plays a significant role in the etiology of Parkinson's disease (PD). Parkinson’s disease impacts about one percent of individuals over the age of 60 and as much as 5% of the persons over the age of 85 [1,2]. Parkinson's disease (PD) is characterized by clinical manifestations such as slowness of movement, stiffness, shivering, and walking difficulties, furthermore uncontrollable symptoms such as problems in sleep disturbance, loss of smell, cognitive loss, and anxiety [3]. Our research includes the molecular docking investigation of the three-dimensional structure of the human alfa-synuclein collected out from Protein Data Bank along with their chemical ligands. Auto Dock 4.2.6 was used in our molecular docking the human alpha synuclein against certain drugs (ligands). Our molecular docking experiment sheds light on an in-silico drug reproposing methodology to alfa-synuclein (αS) modulating as a hopeful PD treatment for patients.